Autolus Therapeutics (NASDAQ:AUTL) vs. Vericel (NASDAQ:VCEL) Head-To-Head Comparison

Autolus Therapeutics (NASDAQ:AUTL) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, risk, profitability, analyst recommendations and dividends.

Earnings and Valuation

This table compares Autolus Therapeutics and Vericel’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Autolus Therapeutics $1.41 million 282.19 -$44.75 million ($1.42) -6.98
Vericel $90.86 million 7.93 -$8.14 million ($0.14) -116.57

Vericel has higher revenue and earnings than Autolus Therapeutics. Vericel is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Autolus Therapeutics and Vericel, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Autolus Therapeutics 0 0 3 0 3.00
Vericel 0 1 2 0 2.67

Autolus Therapeutics currently has a consensus target price of $45.50, suggesting a potential upside of 359.13%. Vericel has a consensus target price of $24.64, suggesting a potential upside of 50.98%. Given Autolus Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Autolus Therapeutics is more favorable than Vericel.

Insider & Institutional Ownership

43.4% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 90.8% of Vericel shares are owned by institutional investors. 4.5% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Autolus Therapeutics and Vericel’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Autolus Therapeutics N/A N/A N/A
Vericel -18.14% -0.99% -0.75%

Risk & Volatility

Autolus Therapeutics has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, Vericel has a beta of 2.75, suggesting that its share price is 175% more volatile than the S&P 500.

Summary

Autolus Therapeutics beats Vericel on 8 of the 14 factors compared between the two stocks.

About Autolus Therapeutics

Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma. It is also developing AUTO4, a programmed T cell therapy that is in Phase I/II clinical trial for the treatment of peripheral T-cell lymphoma; and AUTO6, a programmed T cell therapy for treating neuroblastoma. Autolus Therapeutics plc has a collaboration partnership with AbCellera Biologics Inc. on antibody discovery project. The company was founded in 2014 and is headquartered in London, the United Kingdom.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.